Pacific Biosciences

196 articles with Pacific Biosciences

• Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager for Europe, Middle East, and AfricaIndustry Veteran Will Lead PacBio’s Commercial Footprint Across the Region

  6/8/2021

  Pacific Biosciences of California, Inc., a leading provider of high-quality, long-read sequencing platforms, welcomed Neil Ward to the new role of Vice President and General Manager for the company’s Europe, Middle East, and Africa region to expand and develop the team and infrastructure to capitalize on the immense potential for genomics in this area of the world.

• Pacific Biosciences Further Expands Leadership Team with Appointment of Dr. Catherine Ball to Newly Created Position of Senior Vice President of Research

  5/17/2021

  Kathleen Lynch has joined as Head of Global Government Affairs and Communications and Michele Farmer has joined as Chief Accounting Officer

• Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - May 04, 2021

  5/4/2021

  Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conferences

• Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results

  4/29/2021

  Pacific Biosciences of California, Inc. announced financial results for the quarter ended March 31, 2021.

• Pacific Biosciences Launches New HiFi Sequencing Workflow to Further Improve HiFi’s Industry Leading Accuracy

  4/26/2021

  HiFi Sequencing and Software v10.1 Release on the Sequel II and IIe Systems I ncreases Scalability, Improves Usability, and Unlocks Additional Sample Types to Extend the Value of HiFi Reads

• Pacific Biosciences of California, Inc. First Quarter 2021 Financial Results Call

  4/15/2021

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results on Thursday, April 29, 2021, at 4:30pm Eastern Time.

• Children’s Mercy Kansas City Expands Investment in Pacific Biosciences Sequel IIe Systems to Scale Up Whole Genome Research Initiatives Focused on Rare Disease Diagnosis

  2/24/2021

  Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Children’s Mercy Kansas City, one of the nation’s top pediatric medical centers, has increased its investment in highly accurate HiFi sequencing with four new Sequel IIe Systems to add to its two existing Sequel IIe Systems.

• Pacific Biosciences Sequel II Systems Deployed to Scale-Up Global Viral Surveillance Initiatives Focused on COVID-19Labcorp Using PacBio’s HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.

  2/18/2021

  Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that Labcorp (NYSE: LH), a leading global life sciences company, has increased its commitment to highly accurate HiFi sequencing with the addition of new PacBio ® Sequel ® II Systems.

• 

  PacBio Secures $900 Million Investment to Support Gene Sequencing

  2/10/2021

  Shares of Pacific Biosciences soared more than 21% in premarket trading after it was announced SB Management, a subsidiary of SoftBank Group Corp., will make an investment of $900 million into the company to support its gene sequencing research.

• Pacific Biosciences Grants Equity Incentive Award to New Employee - Feb 05, 2021

  2/5/2021

  Pacific Biosciences of California, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020.

• Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

  1/27/2021

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/ . Date: February 10, 2021 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll

• Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

  1/13/2021

  Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate HiFi sequencing to expand Invitae’s whole genome testing capabilities. “

• Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

  1/8/2021

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Systems to increase its long-read sequencing capabilities for projects including the Darwin Tree of Life (DToL; all eukaryotes in Britain and Ireland) and Aquatic Symbiosis G

• Pacific Biosciences Grants Equity Incentive Award to New Employee

  12/18/2020

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of

• SARS-CoV-2 Viral Genome Sequencing Data Presented from Research Using Pacific Biosciences Technology

  12/16/2020

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced initial findings from the company’s research collaboration with Labcorp that is focused on SARS-CoV-2 and the related immune response to COVID-19. Announced in April 2020 , PacBio and Labcorp are collaborating to develop a production-scale assay for sequencing the complete genome

• Leading UK Core Labs Expand Investment in PacBio Sequencing Systems to Power Life Science Research with HiFi Reads

  12/14/2020

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that three of the United Kingdom’s leading core laboratories have increased their investment in the company’s Single Molecule, Real-Time (SMRT ® ) Sequencing technology. Edinburgh Genomics , Oxford Genomics Centre , and University of Liverpool Centre for Genomic Research ha

• Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock - Nov 11, 2020

  11/11/2020

  Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a price to the public of $14.25 per share.

• Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock - Nov 10, 2020

  11/10/2020

  Pacific Biosciences of California, Inc. announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten public offering.

• Pacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results

  11/2/2020

  Pacific Biosciences of California, Inc. announced financial results for its third quarter ended September 30, 2020.

• Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics

  10/22/2020

  Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In